REPORT ID 6940

United States Cancer Vaccines Market Report 2017

Publish Date
1-Nov-17
Pages
108
Format
Electronic (PDF)

In this report, the United States Cancer Vaccines market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Cancer Vaccines in these regions, from 2012 to 2022 (forecast).

United States Cancer Vaccines market competition by top manufacturers/players, with Cancer Vaccines sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Dendreon
    GlaxoSmithKline
    Merck
    Sanofi
    Amgen
    Biothera
    Isa Pharmaceuticals
    Bristol-Myers Squibb
    Bavarian Nordic
    Antigen Express
    Juvaris Biotherapeutics
    Provectus Biopharmaceuticals
    Aduro BioTech
    Galena Biopharma
    Northwest Biotherapeutics
    Oxford BioMedica
    Inovio Pharmaceuticals
    Vaxon Biotech
    Celldex Therapeutics
    Prima BioMed

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Rophylactic Vaccines
    Therapeutic Vaccines
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Adults
    Children

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Cancer Vaccines Market Report 2017
1 Cancer Vaccines Overview
    1.1 Product Overview and Scope of Cancer Vaccines
    1.2 Classification of Cancer Vaccines by Product Category
        1.2.1 United States Cancer Vaccines Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Cancer Vaccines Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Rophylactic Vaccines
        1.2.4 Therapeutic Vaccines
    1.3 United States Cancer Vaccines Market by Application/End Users
        1.3.1 United States Cancer Vaccines Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Adults
        1.3.3 Children
    1.4 United States Cancer Vaccines Market by Region
        1.4.1 United States Cancer Vaccines Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Cancer Vaccines Status and Prospect (2012-2022)
        1.4.3 Southwest Cancer Vaccines Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Cancer Vaccines Status and Prospect (2012-2022)
        1.4.5 New England Cancer Vaccines Status and Prospect (2012-2022)
        1.4.6 The South Cancer Vaccines Status and Prospect (2012-2022)
        1.4.7 The Midwest Cancer Vaccines Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Cancer Vaccines (2012-2022)
        1.5.1 United States Cancer Vaccines Sales and Growth Rate (2012-2022)
        1.5.2 United States Cancer Vaccines Revenue and Growth Rate (2012-2022)

2 United States Cancer Vaccines Market Competition by Players/Suppliers
    2.1 United States Cancer Vaccines Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Cancer Vaccines Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Cancer Vaccines Average Price by Players/Suppliers (2012-2017)
    2.4 United States Cancer Vaccines Market Competitive Situation and Trends
        2.4.1 United States Cancer Vaccines Market Concentration Rate
        2.4.2 United States Cancer Vaccines Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Cancer Vaccines Manufacturing Base Distribution, Sales Area, Product Type

3 United States Cancer Vaccines Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Cancer Vaccines Sales and Market Share by Region (2012-2017)
    3.2 United States Cancer Vaccines Revenue and Market Share by Region (2012-2017)
    3.3 United States Cancer Vaccines Price by Region (2012-2017)

4 United States Cancer Vaccines Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Cancer Vaccines Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Cancer Vaccines Revenue and Market Share by Type (2012-2017)
    4.3 United States Cancer Vaccines Price by Type (2012-2017)
    4.4 United States Cancer Vaccines Sales Growth Rate by Type (2012-2017)

5 United States Cancer Vaccines Sales (Volume) by Application (2012-2017)
    5.1 United States Cancer Vaccines Sales and Market Share by Application (2012-2017)
    5.2 United States Cancer Vaccines Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Cancer Vaccines Players/Suppliers Profiles and Sales Data
    6.1 Dendreon
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Cancer Vaccines Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Dendreon Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 GlaxoSmithKline
        6.2.2 Cancer Vaccines Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 GlaxoSmithKline Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Merck
        6.3.2 Cancer Vaccines Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Merck Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Sanofi
        6.4.2 Cancer Vaccines Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Sanofi Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Amgen
        6.5.2 Cancer Vaccines Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Amgen Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Biothera
        6.6.2 Cancer Vaccines Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Biothera Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Isa Pharmaceuticals
        6.7.2 Cancer Vaccines Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Isa Pharmaceuticals Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Bristol-Myers Squibb
        6.8.2 Cancer Vaccines Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Bristol-Myers Squibb Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Bavarian Nordic
        6.9.2 Cancer Vaccines Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Bavarian Nordic Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Antigen Express
        6.10.2 Cancer Vaccines Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Antigen Express Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Juvaris Biotherapeutics
    6.12 Provectus Biopharmaceuticals
    6.13 Aduro BioTech
    6.14 Galena Biopharma
    6.15 Northwest Biotherapeutics
    6.16 Oxford BioMedica
    6.17 Inovio Pharmaceuticals
    6.18 Vaxon Biotech
    6.19 Celldex Therapeutics
    6.20 Prima BioMed

7 Cancer Vaccines Manufacturing Cost Analysis
    7.1 Cancer Vaccines Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Cancer Vaccines

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Cancer Vaccines Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Cancer Vaccines Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Cancer Vaccines Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Cancer Vaccines Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Cancer Vaccines Sales Volume Forecast by Type (2017-2022)
    11.3 United States Cancer Vaccines Sales Volume Forecast by Application (2017-2022)
    11.4 United States Cancer Vaccines Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer